Table 2.
Prevalence of CKD in Rivas, Nicaragua from 2012 to 2014
| Variable | Phase 1, 2012a | Phase 2, 2014b | Combined |
|---|---|---|---|
| Total evaluable (n) | 1016 | 211 | 1227 |
| Screened with CKD by MDRD (n) | 400 (39%) | ||
| Not retested (n) | 84 | – | – |
| Retested (n) | 316 | – | – |
| Confirmed CKD by serum creatinine (n) | 43 | 10 | 53 |
| Stage 3A (eGFR 45–59) (n) | 21 | 5 | 26 |
| Stage 3B (eGFR 30–44) (n) | 12 | 4 | 16 |
| Stage 4 (eGFR 15–29) (n) | 8 | 1 | 9 |
| Stage 5 (eGFR<15) (n) | 2 | 0 | 2 |
| Confirmed not CKD (n) | 273 | ||
| CKD observed prevalence | 4.2% (43 of 1016) | 4.7% (10 of 211) | 4.3% (53 of 1227) |
| CKD adjusted prevalencec | 5.3% (54 of 1016) | 4.7% (10 of 211) | 5.2% ([54+10] of 1227) |
–, not applicable.
a
CKD defined as eGFR<60 ml/min per 1.73 m2 using the Chronic Kidney Disease Epidemiology Collaboration equation.
b
New participants enrolled.
c
Adjusted for participants who were screened positive for CKD in phase 1 but were not available for retesting in phase 2.